CKPT Projected Dividend Yield
Checkpoint Therapeutics Inc ( NASDAQ : CKPT )Checkpoint Therapeutics is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of treatments for patients with solid tumor cancers. Co. is evaluating its primary antibody product candidate, cosibelimab, an anti-programmed death-ligand 1 antibody, in an ongoing global, open-label, multicohort clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers. Co. is also evaluating its main small-molecule, targeted anti-cancer agent, olafertinib, an epidermal growth factor receptor (EGFR) inhibitor, as a potential treatment for patients with EGFR mutation-positive non-small cell lung cancer. 20 YEAR PERFORMANCE RESULTS |
CKPT Dividend History Detail CKPT Dividend News CKPT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |